05B4 Tuluc, Madalina - Thomas Jefferson University - Thomas Jefferson University

Madalina Tuluc, MD, PhD

Contact Dr. Tuluc

132 South 10th Street
285R Main
Philadelphia, PA 19107

(215) 955-7524
(215) 923-1969 fax

Most Recent Peer-reviewed Publications

  1. Ciliated Adenosquamous Carcinoma: Expanding the Phenotypic Diversity of Human Papillomavirus-Associated Tumors
  2. Malignant Sarcomatous Transformation of Fibrous Dysplasia
  3. Orbital involvement by NUt midline carcinoma
  4. Salivary duct carcinoma: The predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression
  5. Multicompartment metabolism in papillary thyroid cancer
  6. Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis
  7. Aging effects on pedicled fasciocutaneous flap survival in rats
  8. A Rare Case of Carcinoma Cuniculatum Involving the Larynx in Association with a Saccular Cyst
  9. Malignant Sarcomatous Transformation of Fibrous Dysplasia
  10. Tumor microenvironment in head and neck squamous cell carcinoma
  11. Thyroid Cytology
  12. Recurrent epistaxis and nasal congestion
  13. Current management of locally advanced head and neck cancer: The combination of chemotherapy with locoregional treatments
  14. False-positive fna due to highly sensitive braf assay
  15. Chondrosarcoma of the hyoid bone: Case report and review of current management options
  16. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma
  17. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
  18. Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment RAS and NFκB target stromal MCT4
  19. Cancer metabolism, stemness and tumor recurrence : MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer
  20. Clinical experience transitioning from IMRT to VMAT for head and neck cancer